Welcome to Dividends Inside
Welcome to Dividends Inside!

The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.

Liminatus Pharma, Inc.

LIMN
$0.00 (+ $0.00 + 0.00%)
Last updated: -
LIMN Metrics
Exchange
🇺🇸 NASDAQ XNMS
Nasdaq/NMS (Global Market)United StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS53271X1081
Market Price0.19
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-0.16
Market Cap$19.2M
Book Value-0.06
Price to Book-11.607
Beta0.38
52w High33.66
52w Low0.61
Next Earnings DateN/A
About the Company
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California.
Price History